Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Now Has Problems At Its Dialysis Center In Bessemer, Alabama

Fresenius, the maker of the recalled dialysis drugs GranuFlo and NaturaLyte, is back in the news because its Bessemer, Alabama dialysis center has been closed due to two deaths and five hospitalizations of dialysis patients last month.

Consumer injury attorney Michael J. Evans announced today that he and two other law firms have launched a new website dedicated to providing information and offering legal assistance to people with potential claims caused by dialysis drugs, such as GranuFlo and NaturaLyte, or other dialysis malfeasance. The website is http://www.DialysisLawsuitAttorneys.com.

“My litigation partners and I decided it was time to begin offering legal services to people who may have been injured by the recalled dialysis drugs GranuFlo and NaturaLyte, or who may have suffered injuries due to some other form of negligent conduct by the company performing dialysis,” said Evans.GranuFlo & NaturaLyte Dialysis Drug Recall by FDA

“Fresenius, the maker of GranuFlo and NaturaLyte, not only makes dialysis drugs, but it also provides dialysis services through dialysis centers located throughout the United States.” said Evans.

“The GranuFlo and NaturalLyte recall in 2012 was followed up by the filing of so many GranuFlo lawsuits that they were given multidistrict litigation status and transferred to the federal court in the District of Massachusetts on March 29, 2013,” Evans said.

Evans noted that “a June 17, 2013 AL.com report says that Bessemer Kidney Center, operated by Fresenius in Bessemer, Alabama, was closed in May 2013 after 2 deaths and 5 hospitalizations occurred within a few days. Although an investigation by the Alabama Department of Public Health did not find “a common thread” tying the deaths and hospitalizations together, the investigation did find “deficiencies” that must be addressed with a plan of action before the center can re-open, according to the report on AL.com. The report says that “deficiencies” were found at the dialysis center last year, as well.”

The new website, http://www.DialysisLawsuitAttorneys.com, will focus on more than just GranuFlo and NaturaLyte lawsuits,” said Evans. “We plan to look at other potential cases for people who have been harmed by dialysis mistakes, defective dialysis equipment, or dialysis drugs such as GranuFlo or NaturaLyte.”

[Continue reading…]

Actos Bladder Cancer Risk Shown in May 31, 2012 Study

Actos bladder cancer risks shown in May 31, 2012 study, establishes Actos bladder cancer risk.

Actos, the trade name for the diabetes drug Pioglitazone, is associated with an increased risk of bladder cancer, finds a study pub

lished on bmj.com today.

The results show that more than two years daily exposure to pioglitazone doubles the risk of Actos bladder cancer.

Actos bladder cancer risks were evaluated in a new study reported in MedpageToday.com on May 31, 2012. The study confirms previous studies

showing an Actos bladder cancer risk. According to an excerpt from the article, the Actos bladder cancer risk is clearly established:

Use of the anti-diabetic agent pioglitazone (Actos) is associated with an increased risk of bladder cancer, a nested case-control study confirmed.

Patients with type 2 diabetes who were ever treated with pioglitazone [Actos] had an 83% higher risk for bladder cancer (adjusted rate ratio 1.83, 95% CI 1.10 to 3.05) than those who had never used the thiazolidinedione, according to Laurent Azoulay, PhD, of McGill University in Montreal, and colleagues.

This was a drug-specific effect, because patients taking rosiglitazone (Avandia) did not have an elevated risk (RR 1.14, 95% CI 0.78 to 1.68), the

researchers reported online in

BMJ.

The results of this analysis differed from those of a study being presented this week at the annual meeting of the American Society of Clinical Oncology, which suggested that the bladder cancer risk was a class effect for glitazones.

Other previous efforts to ascertain if pioglitazone [Actos] is associated with bladder cancer have had conflicting results, but the FDA and the Canadian health authorities have added a warning of that risk to the drug’s labeling, and some European countries have restricted its use.

(Emphasis added)

In other articles published today about the study, ScienceCodex reported that the new study shows that 2 years of treatment with Actos doubles the risk of bladder cancer.

(Emphasis added).

Actos Bladder Cancer Resources May 31, 2012: